Headlines

Farydak (panobinostat) now FDA-approved for multiple myeloma

Farydak (panobinostat) now FDA-approved for multiple myeloma

Drug is now sanctioned for people who have received at least two prior standard therapies.

ASCO: Testicular cancer history may indicate greater risk of developing prostate cancer

ASCO: Testicular cancer history may indicate greater risk of developing prostate cancer

Individuals who've had testicular cancer may be at increased risk for prostate cancer, but the overall risk is low, according to a study.

Urine test could help to guide treatment of bladder cancer

A newly developed urine test could help to guide clinicians in the treatment of bladder cancer patients.

Multiple studies are exploring whether e-cigarettes help smokers quit or continue smoking

Multiple studies are exploring whether e-cigarettes help smokers quit or continue smoking

Research continues into whether e-cigarettes help smokers quit or actually worsen their habit.

Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia

Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia

About 10% of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib discontinued their therapy due to disease progression during clinical studies.

New mechanism of acquired resistance to breast cancer drugs discovered

Researchers have discovered that ERBB4 (also known as HER4) is a driver protein in ERBB2-positive tumors that have developed resistance to first- or second-line treatments.

Crucial role of breast cancer tumor suppressor revealed

Cells that contain lower levels of protein profilin 1 in breast tumors have an increased capacity to metastasize and invade other tissues, according to research.

What determines cost-effectiveness of targeted anticancer therapies?

What determines cost-effectiveness of targeted anticancer therapies?

An opinion published in the Journal of Thoracic Disease examines data required to determine the cost effectiveness of cancer treatments.

Post-cancer survival up for Americans, but disparities remain

Post-cancer survival up for Americans, but disparities remain

Study shows biggest improvements in post-cancer survival for people diagnosed between ages 50 and 64.

More than 8 hours of sleep a day associated with increased stroke risk

More than 8 hours of sleep a day associated with increased stroke risk

People who sleep for more than eight hours a day are at increased risk to suffer a stroke, according to a recent study.

Conference Coverage

Novel tool predicts postoperative liver cancer recurrence after transplant

The risk of disease recurrence in liver cancer patients who have undergone a liver transplant can now be more accurately calculated, thanks to new tool.

Surgery may not be necessary for some patients with rectal cancer

Patients with rectal cancer that experienced a complete response had similar 4-year survival rates regardless of whether they had immediate surgery or pursued a watch-and-wait approach.

Long-term outcomes improved by combining bevacizumab with newer chemotherapy regimen for advanced colorectal cancer

A phase III study of patients with metastatic colorectal cancer has indicated that FOLFOXIRI chemotherapy, in combination with bevacizumab, is superior to the standard FOLFIRI chemotherapy with bevacizumab.

Young adults with acute lymphoblastic leukemia (ALL) benefit from therapies developed for children

There is increasing evidence that adolescent and young adult patients with acute lymphoblastic leukemia (ALL) tend to fare better when treated with high-intensity pediatric protocols than standard adult regimens.

PRM-151 therapy well tolerated by patients with advanced myelofibrosis

The compound PRM-151 (PRM) has shown success in reducing progressive bone marrow fibrosis in patients with advanced myelofibrosis.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs